[
  {
    "ts": null,
    "headline": "Healthcare Stocks Rise Tuesday -- Healthcare Roundup",
    "summary": "Healthcare Stocks Rise Tuesday -- Healthcare Roundup",
    "url": "https://finnhub.io/api/news?id=bcca65ff5f2f5ebab8578b45c106c1fd0bf48afa6d60a9e8849618ce4ccc4c0b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748970660,
      "headline": "Healthcare Stocks Rise Tuesday -- Healthcare Roundup",
      "id": 135015854,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Healthcare Stocks Rise Tuesday -- Healthcare Roundup",
      "url": "https://finnhub.io/api/news?id=bcca65ff5f2f5ebab8578b45c106c1fd0bf48afa6d60a9e8849618ce4ccc4c0b"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b294e3b6240bfddc12989b7c22b9826ac742df1d863bc5ec4475ca2db6881cde",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748968440,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 135015855,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b294e3b6240bfddc12989b7c22b9826ac742df1d863bc5ec4475ca2db6881cde"
    }
  },
  {
    "ts": null,
    "headline": "MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest",
    "summary": "MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest",
    "url": "https://finnhub.io/api/news?id=1b788c3d878e11eb4704b662351ff2aa15d97a7b6f61cafbfbd6e3b5d27abc4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748963297,
      "headline": "MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest",
      "id": 134987966,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1b788c3d878e11eb4704b662351ff2aa15d97a7b6f61cafbfbd6e3b5d27abc4b"
    }
  },
  {
    "ts": null,
    "headline": "Constellation and Meta, Merck, Snowflake: Trending Tickers",
    "summary": "Constellation Energy (CEG) has inked a 20-year deal to provide tech giant Meta Platforms (META) with power from its clean nuclear energy plant. Merck (MRK) has reportedly been in talks to acquire Swiss biotech company MoonLake Immunotherapeutics (MLTX) for over $3 billion, according to the Financial Times. Snowflake (SNOW) will buy startup Crunchy Data in an agreement valued at $250 million. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
    "url": "https://finnhub.io/api/news?id=19a4e32d1fabc68576ead0ac5cc9d33fc7bd284109f60cc09dbf68dfb9ca1be1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748957603,
      "headline": "Constellation and Meta, Merck, Snowflake: Trending Tickers",
      "id": 134977624,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Constellation Energy (CEG) has inked a 20-year deal to provide tech giant Meta Platforms (META) with power from its clean nuclear energy plant. Merck (MRK) has reportedly been in talks to acquire Swiss biotech company MoonLake Immunotherapeutics (MLTX) for over $3 billion, according to the Financial Times. Snowflake (SNOW) will buy startup Crunchy Data in an agreement valued at $250 million. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
      "url": "https://finnhub.io/api/news?id=19a4e32d1fabc68576ead0ac5cc9d33fc7bd284109f60cc09dbf68dfb9ca1be1"
    }
  },
  {
    "ts": null,
    "headline": "MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover",
    "summary": "Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for \"more than $3 billion.\"",
    "url": "https://finnhub.io/api/news?id=2648d1c9621c7787fc68ade4df055582fc3e2366088fa45ed80001cd6a0b3129",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748957241,
      "headline": "MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover",
      "id": 134977625,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for \"more than $3 billion.\"",
      "url": "https://finnhub.io/api/news?id=2648d1c9621c7787fc68ade4df055582fc3e2366088fa45ed80001cd6a0b3129"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report",
    "summary": "US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion. While MoonLake turned down the initial offer, talks may be revived. The potential deal signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster cancer drug Keytruda faces patent expiration as early as 2028. MoonLake Immunotherapeutics’ lead development asset sonelokimab is a",
    "url": "https://finnhub.io/api/news?id=2ddc7490cc9b6da262678ee6b4c088515d1269a43ccebd0f3c1e4908656e4753",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748950689,
      "headline": "Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report",
      "id": 134977626,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion. While MoonLake turned down the initial offer, talks may be revived. The potential deal signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster cancer drug Keytruda faces patent expiration as early as 2028. MoonLake Immunotherapeutics’ lead development asset sonelokimab is a",
      "url": "https://finnhub.io/api/news?id=2ddc7490cc9b6da262678ee6b4c088515d1269a43ccebd0f3c1e4908656e4753"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up",
    "summary": "At the heart of the biotech deal is a relatively new drug technology called PD-1/VEGF bispecific antibodies.",
    "url": "https://finnhub.io/api/news?id=d8c11e91cdda04ac4a031dcb145e5c3b8281da1e014df125da66ca6c711a60cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748946600,
      "headline": "Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up",
      "id": 134977430,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "At the heart of the biotech deal is a relatively new drug technology called PD-1/VEGF bispecific antibodies.",
      "url": "https://finnhub.io/api/news?id=d8c11e91cdda04ac4a031dcb145e5c3b8281da1e014df125da66ca6c711a60cc"
    }
  },
  {
    "ts": null,
    "headline": "This Biotech Stock Is Jumping 20%. Why a $3 Billion Merck Offer Could Be a Win-Win.",
    "summary": "This Biotech Stock Is Jumping 20%. Why a $3 Billion Merck Offer Could Be a Win-Win.",
    "url": "https://finnhub.io/api/news?id=5f302720883e695c37540e2f408bed9e87cfb52a5234f16386d8bf8ecf23d892",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748943660,
      "headline": "This Biotech Stock Is Jumping 20%. Why a $3 Billion Merck Offer Could Be a Win-Win.",
      "id": 134984053,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "This Biotech Stock Is Jumping 20%. Why a $3 Billion Merck Offer Could Be a Win-Win.",
      "url": "https://finnhub.io/api/news?id=5f302720883e695c37540e2f408bed9e87cfb52a5234f16386d8bf8ecf23d892"
    }
  }
]